VP-16

From Standard of Care

Revision as of 00:00, 15 January 2001; view current revision
←Older revision | Newer revision→
Jump to: navigation, search

Secondary acute leukemia develops in fewer than 0.5% of patients treated with less than 2000 mg/M2 of drug and in as many as 6% of patients treated with greater than 3000 mg/M2 of VP-16 chemotherapy.

Retrieved from "http://www.standardofcare.com/mwiki/index.php?title=VP-16"
Personal tools